Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wonder if....
all the sellers think that Niagen is not real and that P&G is not real and that all the tests that have and are being performed are not real.
I wish the guy who bought the million shares on Friday's close had saved his buying power for this morning.
There was an article published this morning witch was pulled.
Honig must have gone after them:
This article has been temporarily removed per the author's request.
Follow this author and get email alerts
Follow Bleecker Street Research
I wish I knew what the hell is going on with the PPS. Bought more this morning buy wondering why the sell off.
Picked up another thousand at 4.92. I first thought Frost was the purchaser of the million shares but obviously not. Although I like picking up cheap shares here, I don't understand why the dump, but what do I know, i couldn't buy a million shares and he could.
Just received my copy of Life Extension's monthly magazine and there is an excellent article on Nicotinamide riboside. Of course they sell a supplement containing Niagen. LEF has a very large audience in the supplement market.
Poster on a different board thinks the purchaser of the million shares is unloading. I would have thought that CDXC management would have precluded that from happening BUT who knows. JMO
Thanks GMS for that analysis. Great to have you here. I think the chart is setting up for a run at our resistance at $6. It would be great if we can hold this level and then make the run at it. That resistance has been there for a long time and once gone, we could have clear upside sailing, especially with the company performing the way it is. It would also be nice to see some institutional buying come in. I have been looking but have not seen any reporting new holdings. JMO
I joined you by adding some here.
I want to thank all the posters to this board. I know that CDXC is going to be a great investment and hope we get more and more of the shareholders, new and old, posting here. The more information that gets posted, the better for all of us. I can't wait till we break the $6 resistance level and move on up from there.
I thought this statement in today's news release is very interesting.
“The development of nicotinamide riboside for Cockayne Syndrome and other pharmaceutical indications is starting to accelerate and we are currently evaluating strategic options for these undervalued pharmaceutical opportunities.”
Somethings up in the near future. JMO
Securities offered by ChromaDex
1,117,022 shares of common stock
Offering price at $4.70 per share.
Use of proceeds
"We intend to use $4,857,948.52 of the net proceeds from the offering to retire in full our outstanding indebtedness owed to Hercules Technology II, L.P. We will use the remaining net proceeds for general corporate purposes."
I think this is great use of the funds. Get rid of debt and the interest expense that goes along with it. I hope Frost buys the offering or an institution that would become another of our long term holders. JMO
Hi DavenCT...
"Did the BoD ASK Dunkerley to leave and let him 'save face?' Is there any chance of Dunkerley's financial games have been played on CDXC shareholders?"
You could be correct that the BOD asked him to leave or maybe he decided to leave to not get CDXC involved. However, if he was playing any financial games at CDXC, I think we should thank him for the results of where we are now. BTW, JMO
Hi RM...I love the chart on SEED. Close to buying some shares. What are your thoughts on the sells by instututions?
insert-text-here
I own shares of CDNL also. My thoughts are that it's going to take a while to eat through all the selling that is going to take place in the short term. Great news would be great because it would bring in new buyers. JMO
Hi Karen...
The link is in the news just below the chart above the messages.
ChromaDex to Present at the 2016 Marcum MicroCap Conference on June 1, 2016
University Researchers Show Vitamin Nicotinamide Riboside is an Effective Tool for Managing the Negative Effects of Obesity and Diabetes
New published study shows a unique form of vitamin B3, nicotinamide riboside, may help with weight gain and glycemic control as well as protect nerves from diabetic damage
Hi yorky. Thanks for the info. Makes me feel better knowing that shorts will have to cover as we move back up.
Always surprises me when Someone unloads a lot of shares right before acompany is going to present at a conference. I know that there are a lot of reasons why people sell but the day before. Ugh
I bought some more CDXC this morning and also some OPK yesterday. I like the fact that the company is attending conferences and trying to attract new investors. That is what we are going to need to get us through the $6 resistance. JMO
ChromaDex to Present at the 2016 Marcum MicroCap Conference on June 1, 2016
IRVINE, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Financial Officer, Tom Varvaro, will present at the 2016 Marcum MicroCap Conference. The investor conference will be held on June 1-2, 2016 at the Grand Hyatt New York in New York, N.Y.
Varvaro is scheduled to present on June 1 at 3:30 p.m. ET. ChromaDex management will also be attending one-on-one meetings with the investment community throughout the day.
The Marcum MicroCap Conference is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The 2016 Conference will be two full days with feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders and the opportunity to meet with management of presenting companies on a one-on-one basis.
This event attracts fund managers and high net worth investors who focus on small cap equities. Over 2,000 participants from all segments of the microcap market participated in 2015. Attendees included senior management, finance and legal executives, venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, buy- and sell-side analysts, and service providers to the microcap marketplace.
I found this...which I don't understand. Did Gregory White buy these today?
TOP INSTITUTIONAL HOLDERs
White (Gregory L)
3.3M $165,662 +100% 1.0% --
TOP MUTUAL FUND HOLDERS
and this....
SHAREHOLDERS
TOP SHAREHOLDERS
Large Block Owners 1
Buyers 5/24/16 3,306,628 $0.17 1.0%
I can't find any info on insider share holdings for RXMD. Can anyone help?
Well HSHS is getting so cheap that any news from the company should drive the PPS much higher. JMO
Thanks g7. I first got interested in OPK thru the Frost connection. I have owned and followed (CDXC) Chromadex Corp for a long time, which led me to Frost.
First post here on the OPK board. I took a starter position today at $10.06. Everyone posting on the board talks fundamentals. I love the OPK chart. This is just my opinion but it appears to me that a perfect Head and shoulders reversal bottom pattern is being put in place. I will buy more when the PPS breaks out above $11.50. We have tested that price 2 times already and there is also a gap that needs to be filled at $12.00. Then it's off to the races. But again, JMO
OPk, Opko Health, CDXC's largest shareholder as I am sure you all know, looks great on the charts. Nice head and shoulders pattern setting up. JMO
The problem this morning is no one is buying. They are waiting for the heavy hitters to do their work while they ride. Huge drop off from yesterdays volume. JMO
Picked up a few more shares today on this pull back. These are going to be cheap shares when we we break through $6.
I'm with you Dragon. My 10,000 became 3333, but I have picked up shares since. I'm holding because I don't think that the good news is anywhere out there yet. As they do these conferences, CDXC will get exposure.A big plus is also the P&G relationship. If that happens then we will really take off. JMO, but holding for the long term.
JMO...but CDNL bounced off the 200 SMA this morning after being stopped there the last time we were up here. I think we may pull back for a few days which is not unheard of when forming a flag pattern. Then we should make a very strong run at the 200 SMA and break through it. That is just my opinion though. BTW....I will be buying more shares as we pull back just as I did on the last pull back we had. Long and strong and holding for a long ride in our PPS.
ChromaDex to Present at the 17th Annual B. Riley & Co. Investor Conference on May 26, 2016
IRVINE, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today its Chief Executive Officer and Founder, Frank Jaksch, will present at the 17th Annual B. Riley & Co. Investor Conference. The investor conference will be held on May 25-26, 2016 at the Loews Hollywood Hotel in Los Angeles, California.
Mr. Jaksch is scheduled to present on Thursday, May 26th at 3:30 p.m. Pacific Time. ChromaDex management will also be attending one-on-one meetings with institutional investors throughout the day.
If you would like to request a one-on-one meeting with ChromaDex management, please contact your B. Riley & Co. representative.
About B. Riley & Co.:
B. Riley & Co., LLC is a leading investment bank which provides corporate finance, research, and sales & trading to corporate, institutional and high net worth individual clients. Investment banking services include initial, secondary and follow-on offerings, institutional private placements, and merger and acquisitions advisory services. The firm is nationally recognized for its highly ranked proprietary equity research. B. Riley & Co., LLC is a member of FINRA and SIPC. For more information, please visit www.brileyco.com.
Hi BigKat1...I would have agreed with you a very short time ago but I think things are changing now that we are listed. Going to investment conferences to introduce the company to profesionals is one example.
Another example....From the conference call..."We also recently added the Breah Ostendorf our new Director of Marketing. Breah comes to us from Aveda and Estee Lauder Company as well as having extensive previous experience with Cargill. So she has a breath of experience in the natural products space. She's going to helping with myself as well as Will Black related to marketing development programs we have for our novel ingredient platform, as well as public relations campaigns as we start to really look towards driving consumer awareness and having a strategy for pursuing ChromaDex's plan of consumer awareness through a public relations campaign."
Things are looking up, We are in for a good ride. JMO
Great job oldguy. With age comes wisdom. It would have hard to sell in the six's. They came and went so fast. Hoping we get another run up tomorrow.
Here is the link for the transcript of today's conference call
http://seekingalpha.com/article/3975426-chromadexs-cdxc-ceo-frank-jaksch-q1-2016-results-earnings-call-transcript?app=1&auth_param=nk83r:1bjk8c7:dfbdc843a6821e067db796027f7710de&uprof=44&dr=1
ChromaDex Names Will T. Black to its Executive Team as Vice President, Sales and Marketing
IRVINE, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Will Black has joined the company as Vice President of Sales and Marketing.
Black has held multiple leadership positions in the nutrition and health industry over the last 25 years. Most recently, Black was COO of Natreon, Inc., a New Jersey-based botanical ingredient company. Prior to Natreon, he held executive positions as global head of marketing and VP of marketing and communications at DSM Nutritional Products, in Basel, Switzerland and Parsippany, NJ respectively. Before DSM, Black held senior sales, marketing, business development and strategy development positions at The Solae Company, the initial nutritional ingredient business group of the DuPont Company.
Commenting about the appointment, Black said, “I have known ChromaDex and have followed their impressive growth and success for a number of years. I am very excited and proud to join their leadership team and look forward to working with the rest of the dedicated management team at ChromaDex and their Board.”
Frank Jaksch, Co-Founder and CEO commented, “We are delighted to have Will as part of the ChromaDex team to help lead our future growth initiatives. His business experience and background are a great fit with our science and evidence-based culture and professional approach to the nutrition and health industry.”
Just a reminder...ChromaDex First Quarter 2016 Conference Call
Monday, May 16, 2016 8:00 a.m. PT.
Very interested in seeing if companies that were at yesterdays conference start to buy CDXC today. It should show in the volume numbers.
Barchart.com %100 buy
http://www.barchart.com/opinions/stocks/CDXC
Actually, I think I have the GP for ingredient sales incorrect. I think it should be 54%.
Net sales $4,600,000
Cost of sales $2,099,000
---------
Gross profit $2,484,000
Gross profit is net sales less the cost of sales and is affected by a number of factors including product mix, competitive pricing and costs of products and services.
The gross profit on ingredients for the Three months ending April 2, 2016 as a % of net sales was 46%. The majority of the increase of ingredient sales was due to increased sales of “NIAGEN®.”.
The increased gross profits for the ingredients segment is due to the increased sales of the ingredient portfolio we offer, coupled with lower prices from our suppliers due to increased purchase volumes.
Just think what the gross profit will be when we are making our ingredients in our own plant.
·